Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study by Antonia, Scott, Prof, Goldberg, Sarah B, MD, Balmanoukian, Ani, MD, Chaft, Jamie E, MD, Sanborn, Rachel E, MD, Gupta, Ashok, MD, Narwal, Rajesh, PhD, Steele, Keith, PhD, Gu, Yu, PhD, Karakunnel, Joyson J, MD, Rizvi, Naiyer A, Prof

Get full text

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study by Hellmann, Matthew D, Dr, Rizvi, Naiyer A, Prof, Goldman, Jonathan W, MD, Gettinger, Scott N, MD, Borghaei, Hossein, DO, Brahmer, Julie R, MD, Ready, Neal E, Prof, Gerber, David E, MD, Chow, Laura Q, MD, Juergens, Rosalyn A, MD, Shepherd, Frances A, Prof, Laurie, Scott A, MD, Geese, William J, PhD, Agrawal, Shruti, PhD, Young, Tina C, MS, Li, Xuemei, MD, Antonia, Scott J, Prof

Get full text

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, s... by Rizvi, Naiyer A, Dr, Mazières, Julien, Prof, Planchard, David, MD, Stinchcombe, Thomas E, MD, Dy, Grace K, MD, Antonia, Scott J, MD, Horn, Leora, MD, Lena, Hervé, MD, Minenza, Elisa, MD, Mennecier, Bertrand, MD, Otterson, Gregory A, MD, Campos, Luis T, MD, Gandara, David R, MD, Levy, Benjamin P, MD, Nair, Suresh G, MD, Zalcman, Gérard, Prof, Wolf, Jürgen, Prof, Souquet, Pierre-Jean, MD, Baldini, Editta, MD, Cappuzzo, Federico, MD, Chouaid, Christos, MD, Dowlati, Afshin, MD, Sanborn, Rachel, MD, Lopez-Chavez, Ariel, MD, Grohe, Christian, Prof, Huber, Rudolf M, Prof, Harbison, Christopher T, PhD, Baudelet, Christine, PhD, Lestini, Brian J, MD, Ramalingam, Suresh S, Prof

Get full text